MedTrace Logo

Evaluation of Quality of Life After Facial Hyaluroic Acid Injections Following Treatment for Breast Cancer.

NCT07425548 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-04-16

No results posted yet for this study

Summary

Breast cancer, the most common cancer in women, is increasingly managed as a chronic disease thanks to therapeutic advances. However, treatments such as chemotherapy and hormonotherapy often induce premature menopause in younger women, leading to skin aging, atrophy, and distressing symptoms that negatively affect quality of life. These cutaneous effects are frequently overlooked despite their psychological and social impact. Hyaluronic acid injections, already well established in aesthetic and reconstructive medicine, may offer a safe, minimally invasive option to restore skin quality, improve self-esteem, and enhance overall well-being in breast cancer survivors. This study aims to assess their efficacy and safety in this specific population.

Conditions

Interventions

DEVICE

Inject of hyaluronic acid in the face

The patient may receive up to 1 ml (volume of one syringe) of each of the three HA references (between 1 ml and 3 ml maximum). The HA reference(s) to be injected will be chosen on the basis of the investigator's assessment and the patient's desired correction.

Sponsors & Collaborators

  • Ruban Rose

    collaborator UNKNOWN

  • Institut Bergonié

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-07-31
Completion
2027-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07425548 on ClinicalTrials.gov